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Epithelial ovarian cancer (EOC) is the gynecological malignancy with the highest death rate, 
characterized by frequent relapse and onset of drug resistance. Disease diagnosis and 
therapeutic follow-up could benefit from application of molecular imaging approaches, 
such as magnetic resonance imaging (MRI) and magnetic resonance spectroscopy 
(MRS), able to monitor metabolic and functional alterations and investigate the underlying 
molecular mechanisms. Here, we overview the quantitative alterations that occur during 
either orthotopic or subcutaneous growth of preclinical EOC  models. A common feature 
of 1H MR spectra is the presence of a prominent peak due to total  choline-containing 
metabolites (tCho), together with other metabolic alterations and MRI-detected morpho-
functional patterns specific for different phenotypes. The tCho  signal, already present at 
early stages of tumor growth, and changes of diffusion-weighted MRI parameters could 
serve as markers of malignancy and/or tumor response to therapy. The identification 
by MRS and MRI of biochemical and physiopathological fingerprints of EOC disease in 
preclinical models can represent a basis for further developments of non-invasive MR 
approaches in the clinical setting.
Keywords: MRi, magnetic resonance spectroscopy, Dwi, ADC, epithelial ovarian cancer, target therapy, 
animal model
inTRODUCTiOn
Epithelial ovarian cancer (EOC) is the fifth cause of cancer-related deaths among women (1), leading 
to about 140,000 deaths worldwide per year. Standard treatment for advanced-stage EOC is debulk-
ing surgery followed by platinum-based chemotherapy, with high response rates, but most of these 
patients will eventually relapse. Several drugs are available to treat recurrences; however, clinical 
responses remain short-lived and lead to only marginal improvements in survival of patients with 
platinum-resistant disease (2).
Prognostic and predictive biomarkers of therapy response need to be identified, and novel 
approaches of drug response assessment need to be developed to validate additional biological end 
points.
Early detection of response to cancer treatment frequently presents a challenge, as many new thera-
pies lead to inhibition of tumor growth rather than to tumor shrinkage. Among the new therapeutic 
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agents under clinical development, those with relative late effects 
could strongly benefit from an early indication of tumor response 
to treatment. Novel non-invasive methods to monitor or predict 
response to treatment, therefore, need to be developed.
Magnetic resonance spectroscopy (MRS) is a non-invasive 
imaging method that can be employed to monitor metabolism 
alterations that are associated with early drug target modulation 
(3) and can be predictive of cancer response to treatment (4). 
After controversial results in the differentiation of benign vs. 
malignant lesions in EOC patients, probably due to the het-
erogeneous nature of this disease (5), recent clinical studies are 
evaluating the role of the altered spectral pattern as an indicator 
of response during treatment of malignant disease rather than as 
initial diagnostic tool.
Magnetic resonance imaging (MRI) is the standard modal-
ity for the local staging of gynecological malignancies but 
has several limitations, particularly for lymph node staging 
and evaluation of peritoneal carcinomatosis. Recent growing 
interest is addressed to functional imaging modalities, such 
as diffusion-weighted MRI (DWI), a unique technique that 
provides tissue contrast by exploiting the restricted water 
mobility within hypercellular tumors to increase the contrast 
between these lesions and surrounding tissues. Using quantita-
tive measurement of apparent diffusion coefficient (ADC) or 
other perfusion-related parameters, DWI provides a new tool 
for better distinguishing malignant tissues from benign tumors 
(6) and can aid in early monitoring of treatment efficacy in 
patients with advanced EOC (7). Moreover, the capability of 
DWI to detect alterations at cellular level rather than in the 
entire tumor mass could be crucial in the assessment of early 
response to a targeted therapy.
Important advances in our understanding of the molecular 
EOC pathogenesis and tissue heterogeneity were achieved by 
using appropriate preclinical models that approach the complex-
ity of this disease in humans. Proper preclinical models that 
mimic tumor behavior and microenvironment involvement in 
patients are also essential for the evaluation of novel treatments 
(8, 9). Among these, models of spontaneous EOC in experimental 
animals (10, 11) or genetically modified animals (12, 13) have 
been developed, but their use remains limited because of the 
long latency to tumorigenesis and the heterogeneity in the tim-
ing of tumor development. EOC cell lines derived from ascites 
or primary ovarian tumors have been extensively used for study-
ing tumor growth and response to treatment (14). Xenografts 
derived from intraperitoneal (i.p.) injection of human EOC cells 
in immunodeficient mice are relatively rapid to generate and 
develop tumor masses mimicking tumor diffusion in patients; 
together with subcutaneous (s.c) xenografts, these models have 
been widely used for studying the mechanisms controlling tumor 
growth and chemosensitivity. An alternative orthotopic EOC 
model can be generated by directly engrafting onto the ovary 
of female mice a piece of tumor tissue derived from an ovarian 
tumor xenograft (15).
In this short review, we will discuss the significance of meta-
bolic and functional features, respectively, detected by MRS and 
DWI in different EOC preclinical models, focusing on aspects of 
metabolic reprogramming occurring in response to anticancer 
treatment strategies. In spite of the growing interest in the use of 
MRI (especially DWI) techniques in ovarian cancer clinical stud-
ies (16–18), a still limited number of papers have been published 
on in  vivo experimental EOC models, mainly due to inherent 
experimental difficulties. For this reason, we decided to also 
include, in this review, some reports presented at prestigious peer 
reviewed international conferences (with abstracts published in 
copyrighted proceedings), although not yet translated into in 
extenso articles.
MeTABOLiC FeATUReS DeTeCTeD BY 
IN VIVO 1H MRS in eOC XenOGRAFTS
Typical 1H MR spectra acquired from vital areas of EOC models 
obtained by either s.c. or i.p. implantation of human EOC cell 
lines of different origins (19, 20) in immunocompromised mice 
(21, 22) are reported in Figures  1A–F. The choice of an s.c. 
implant relies on its simplicity and the short time (about 2 weeks) 
required to develop solid masses. The i.p. model, instead, reca-
pitulates peritoneal spread, mimicking typical features of EOC 
growth and dissemination observed in patients. As shown in 
Figure  1, a prominent 1H MRS signal at 3.2 parts per million 
(ppm) arises from the trimethylammonium headgroups of the 
total choline-containing metabolites (tCho). This peak could be 
clearly detected and quantitated in all investigated EOC models at 
different times of tumor growth. A complete set of MRS analyses 
at different echo times and at different time points during tumor 
growth, together with the application of a quantitative method 
including measurements of water T2 and content (21), allowed 
quantification of the spectral changes occurring over time. The 
tCho level was found to range between 2 and 6 mM in all analyzed 
xenografts (Figures 1A–F).
According to high resolution 1H MRS analyses of cancer cell 
(23) and tissue extracts (21, 24), the tCho peak mainly comprises 
contributions from phosphocholine (PCho), glycerophospho-
choline (GPCho), and free choline (Cho). These analyses showed 
that the PCho/tCho ratio in all cells used for implants shown in 
Figure 1 was greater than 0.70 (21, 24).
Besides tCho, multiple signals arising from the glutamine and 
glutamate pool (Glx), myo-inositol (Ins), and taurine (Tau) are 
also detected in the spectra of EOC xenografts (Figures 1A–D). 
Xenografts obtained from s.c. implantation of SKOV3.ip cells 
[a highly tumorigenic cell variant of the ATCC SKOV3 cell line, 
endowed with a twofold higher HER2 overexpression level (14)], 
showed that the mean tCho content ranged from 2.9 to 4.5 mM 
(with a PCho/tCho ratio of 0.90). In the SKOV3.ip s.c. model, 
the Glx signal was detected at early stages of tumor growth and 
decreased at later stages, while Ins increased in vital areas of the 
tumors (21). When the tumor reached a size larger than 400 mm3, 
an increase in lipid (Lip) signal at 1.3 ppm was also observed in 
“normal appearing” areas in which the presence of micronecrosis 
was detected. Spectral editing ensured that this signal was mainly 
due to lipids rather than to lactate (Lac) (21).
An increased Lip resonance was also observed in the viable 
part of i.p. implants, either OVCA432 (Figure  1B) or SKOV3.
ip models (Figure  1D), compared with the corresponding 
s.c. implants (Figures  1A,C, respectively). This was due to the 
FiGURe 1 | Typical in vivo 1H MRS spectra acquired at 4.7 T from vital areas (as detected by T2-weighted MRi) of xenografts of about 400–600 mm3 
obtained in SCiD mice by (A) subcutaneous (s.c.) implantation of OvCA432 cells (ATTC cell line derived from patient ascite), (B) intraperitoneal (i.p.) 
implantation of OvCA432 cells, (C) s.c. implantation of the SKOv3.ip cells [a cell line obtained by in vivo passage and subsequent in vitro culture of 
the HeR2-positive ATTC SKOv3 cell line (14)], (D) i.p. implantation of SKOv3.ip cells, (e) s.c. implantation of iGROv1 cells (ATTC cell line derived 
from human primary ovarian cancer), and (F) s.c. implantation of OC316 cells (cell line derived from patient ascite). All these EOC models were 
examined between 26 and 50 days post implantation (dpi). Peak assignment: Glx, glutamine plus glutamate; Ins, myo-inositol; Tau, taurine; tCho, total choline-
containing compounds; Cr + PCr, creatine plus phosphocreatine; Lip, lipids; Lac, lactate. Abbreviation: ppm, part per million. Further details in Ref. (22) for spectra 
in (A,B), Ref. (21) for spectra in (C,D), and Ref. (24) for spectra in (e,F).
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presence of round-shaped structures compatible with lipid aggre-
gates detected by H&E staining in ex vivo analyses (21).
Peculiar spectral profiles have also been observed in s.c. xen-
ografts derived from OC316 and IGROV1 cells (Figures 1E,F). 
These patient-derived EOC cell lines have been identified as 
prototypes of highly and poorly glycolytic EOC cells, respec-
tively (25), based on measurements of glucose consumption 
and lactate production rates in vitro, as well as assessment of 
expression levels of glycolysis-associated genes. Besides the 
tCho and lipid signals, high resonances arising from Tau and 
Lac were detected in the spectra of “glucose addicted” EOC 
xenografts (OC316)  –  but not in those of the low glycolytic 
IGROV1 EOC model. The Lac resonance could be isolated 
from the partially overlapping Lip resonance in the in vivo 1H 
MR spectra of the OC316 model by exploiting the property of 
the Lac signal to be reversed when acquired with an echo time 
(TE) of 136 ms and the property of Lip signal to be decayed at 
TE = 136 ms due to its short T2 value, as shown in the lower 
spectrum of Figure  1F and confirmed by bioluminescence 
metabolic imaging (24).
Overall, this body of evidence showed that an elevated tCho 
peak was the most common feature of in vivo 1H MR spectra of 
the investigated EOC models, in agreement with similar findings 
reported for clinical EOC lesions (26–28). Moreover, thanks to 
the shorter echo times achievable in preclinical studies [about 
20 ms vs. 135 ms typically used for clinical MRS and 31P MRS and 
spectroscopic imaging (MRSI) examinations], we could observe 
and quantify several other metabolites, which give a more detailed 
picture of tumor metabolism and may allow for a more extensive 
“metabolic targeting.”
THe tCHO PeAK AS A MARKeR 
OF MALiGnAnCY AnD ReSPOnSe 
TO THeRAPY
The concentration levels of the tCho peak components depend 
on the activity rates of multiple enzymes involved in anabolic and 
catabolic pathways of the agonist-activated phosphatidylcholine 
cycle (29). Alterations in the levels of the tCho components in 
cancer may result from changes occurring in the activity rates 
of multiple enzymes of this cycle under the dysregulated control 
exerted by oncogene-driven cell signaling cascades (23, 30). 
An  increase in the tCho content has been indicated as a bio-
marker for distinguishing malignant from benign lesions in the 
breast (31, 32) and has been detected in a variety of other cancer 
cells and tissues (23), including EOC cells (19, 20) and clinical 
lesions (19, 20, 33). In particular, a 4- to 7-fold increase in PCho 
detected in a series of human EOC cell lines was associated with 
a 12- to 25-fold activation of choline kinase (ChoK) and a 5- to 
17-fold activation of phosphatidylcholine-specific phospholipase 
C (PC-PLC) (20).
A number of preclinical studies have been addressed to evalu-
ate the role of tCho and its components (especially PCho) as pos-
sible markers of tumor progression and response to therapies in 
different types of cancers (23). Among these, recent investigations 
also focused on MRS-detected metabolic effects induced on EOC 
models by anticancer treatments.
Reduction of the tCho content of SKOV3.ip xenograft after 
cytotoxic treatments suggests that this signal could be a potential 
biomarker of treatment response. Decreased tCho levels and 
increased Lac content, associated with an increase in diffusion 
parameters (both diffusion and perfusion components), were 
found to be induced in a SKOV3.ip xenograft model by trabectedin 
(a new marine-derived antitumor agent, which has shown activ-
ity in multiple tumor types, including EOC). The detected tCho 
reduction suggests that this signal could be a potential biomarker 
of trabectedin response, while the Lac increase likely reflects the 
activation of lactic dehydrogenase (LDH) as a consequence of a 
cytotoxic damage to the cancer cells (34).
The effects exerted on tumor growth and metabolism by pan-
thetine, a derivative of vitamin B5 and precursor of coenzyme 
A, were investigated by Penet et al. (35) using MRI/MRS in an 
orthotopic model of ovarian cancer obtained by engrafting a 
piece of OVCAR3 tumor tissue onto the ovary of SCID female 
mice. Pantethine treatment resulted in slower tumor progression, 
decreased levels of PCho and phosphatidylcholine, and reduced 
metastases and ascites occurrence.
A marked tCho reduction has also been observed in vitro (in 
SKOV3.ip cells) and in vivo (in SKOV3.ip s.c. xenografts) upon 
treatment with the competitive PC-PLC inhibitor tricyclodecan-
9-yl-potassium xanthate (D609). The in  vivo tCho reduction 
was associated with increases in the T2 and ADC mean values, 
along with reduced Ki67 index and HER2 content, suggesting 
that PC-PLC plays an important role in HER2-driven EOC cell 
signaling and tumorigenicity (36).
pH ALTeRATiOnS in eOC MODeLS AnD 
iTS POTenTiAL eFFeCTS On CAnCeR 
TReATMenT
The tumor microenvironment plays a key role in tumor malig-
nancy (37). In particular, microenvironment acidity has been 
shown to have a role in the resistance to chemotherapy, prolifera-
tion, and tumor progression. The causes of acidic extracellular pH 
in tumors have not yet been fully elucidated, although important 
contributions probably arise from deficiencies in blood perfusion, 
metabolic abnormalities associated with transformation, and an 
increased capability for transmembrane pH regulation (23).
31P MRS and spectroscopic imaging offers the most power-
ful approaches currently available to non-invasively measure 
extracellular pH (pHe) and intracellular/extracellular pH gradi-
ent (ΔpH) in intact cancer cells and tissues (38, 39). In fact, by 
measuring the chemical shift difference between the exogenous 
cell-impermeant 31P reporter 3-aminopropyl phosphonate reso-
nance (3-APP, administered i.p. immediately prior to the MRI/
MRS analyses) and that of α-ATP, the acidic pHe (6.7–6.8) for 
s.c. and i.p. SKOV3.ip models has been measured at 30–35 dpi. 
The intracellular pH (pHi) measured from the chemical shift 
difference between Pi and α-ATP was 7.3 in s.c. and 7.1 in i.p. 
xenografts (21).
An emerging technique, acidoCEST-MRI, utilizes iopromide, 
a contrast agent that contains two chemical exchange saturation 
transfer (CEST) effects and can assess in  vivo pHe more accu-
rately and with a higher spatial resolution than 31P MRS (40). 
FiGURe 2 | Differential response to veGF neutralization of two eOC models (OC316 and iGROv1) characterized by in vitro different glucose 
consumption and lactate production rates. In the “glucose addicted” model, (A) an average increase of ADC is present corresponding to increased necrotic 
areas. In the IGROV1 model, (B) the A4.6.1 mAB induces a cell damage that can be observed as “cell swelling,” which causes the ADC reduction in the mean value 
and the right-hand shift of the ADC peak. Further details in Ref. (24).
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AcidoCEST-MRI was applied to the orthotopic (i.p.) SKOV3 
model to investigate the relationship between pHe, vascular 
perfusion, and tumor volume (40). This tumor model was mildly 
acidic, with an average pH of 6.88, in agreement with our findings. 
Additionally, larger tumors were found to be more acidic. A lower 
vascular perfusion allowed for an elevated lactic acid production, 
thus causing an increase in tumor acidosis.
These pH alterations observed in EOC models can reflect 
microenvironment alteration in EOC patients’ cancer lesions and 
may modulate their response to conventional or targeted thera-
pies. The negative pH gradient detected in EOC models impairs 
the uptake of weakly basic drugs but can facilitate a selective 
retention by tumor tissues of drugs behaving as weak acids. MR 
techniques provide unique tools to selectively investigate these 
aspects in vivo.
DiFFeRenCeS in CYTOTOXiC AnD 
CYTOSTATiC DRUGS’ eFFeCTS AS 
DeTeCTeD BY IN VIVO Dwi AnD MRS
Early monitoring of treatment efficacy in patients with advanced 
EOC can be achieved using DWI and ADC mean values and 
distributions. In particular, the shape of the ADC distribution 
(in terms of skewness and kurtosis) has been proven to reflect 
chemotherapy response in patients (7, 41), as well as in EOC 
models (14, 24).
By analyzing ADC mean values and distributions, differences 
in cytotoxic and cytostatic effect can be observed largely before 
tumor shrinkage. In fact, cytostatic treatment effects can be 
observed during or up to 48 h after the end of treatment due to cell 
swelling, which results in an ADC decrease during the treatment, 
in absence of any detectable alteration in tCho level. Although 
cell swelling is a phenomenon that occurs during all treatments 
(it is in fact the first manifestation of almost all forms of injury 
to cells), it is dominated by cell death when a cytotoxic agent is 
administered resulting in an increased extracellular space, which 
can be observed as an increased ADC, associated with a tCho 
reduction. Notably, the effect of a cisplatinum-based treatment 
on the SKOV3.ip model (s.c. implant) was to reduce the ADC 
mean value (14). On the same EOC model, cytotoxic agents, such 
as D609 or trabectedin, induced a marked mean ADC increase 
associated with tCho reduction (34, 36).
eOC MODeLS wiTH DiFFeRenT 
GLYCOLYTiC PHenOTYPeS HAve 
DiFFeRenT ReSPOnSeS TO A HUMAn 
veGF neUTRALiZinG mAB AS 
DeTeCTeD BY IN VIVO MRS AnD Dwi
Xenografts obtained from OC316 and IGROV1 patient-derived 
EOC cells (described in paragraph 2) were used to investigate the 
effects on glucose metabolism of A4.6.1, a human VEGF neutral-
izing mAB bearing the same CDR region as bevacizumab (24).
In the “glucose addicted” OC316 xenografts, A4.6.1 caused a 
dramatic depletion of glucose and an exhaustion of ATP levels in 
tumors associated with the presence of large necrotic areas and 
partial tumor regression. Different behavior was observed in the 
IGROV1 xenograft where metabolism remained unaltered after 
anti-VEGF treatment associated with a minor effect on tumor 
growth. Functional links between AMPK pathway and therapeu-
tic responses to VEGF neutralization have also been detected in 
EOC models.
Different ADC distributions characterized the response to 
VEGF neutralization of those two EOC models. In fact, as early 
as after 1  week of treatment, in the “glucose addicted” OC316 
model, a cytotoxic effect of the anti-VEGF treatment could be 
observed as increased mean ADC (Figure 2A). This effect could 
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be attributed to an increase in the extracellular space in agree-
ment with microscopic or macroscopic areas of necrosis detected 
by histology (24) and associated with a significant delay in tumor 
growth. Opposite effect (ADC reduction) can be detected in 
the IGROV1 xenografts, where anti-VEGF treatment probably 
induces a cytostatic effect associated with a minor delay in tumor 
growth (Figure  2B). Moreover, the perfusion component [in 
terms of vascular signal fraction (VSF)], i.e., the component of 
fast diffusing spins (42), is reduced after anti-VEGF therapy, more 
pronounced in the OC316 than in the IGROV1 xenografts.
Prospectively, in vivo lactate and ADC quantitation and their 
monitoring following anti-VEGF treatment by MRI/MRS could 
represent non-invasive tools for the identification of “glucose 
addicted” EOC tumors and for predicting their clinical responses 
to bevacizumab and/or other antiangiogenic drugs.
FUTURe PROSPeCTiveS wiTH 
RADiOLABeLeD COMPOUnDS FOR 
POSiTROn eMiSSiOn TOMOGRAPHY
Positron emission tomography (PET) imaging is mainly used to 
visualize general tumor processes, such as glucose metabolism 
using 18F-fluorodeoxyglucose (18F-FDG) and DNA synthesis 
using 18F-fluorodeoxythymidine (18F-FLT), as tools to predict 
prognosis and response to therapies (43, 44). More specific 
labeled ligands have been evaluated for specific targets, includ-
ing immunotherapy components (64Cu-labeled anti-CA125 
monoclonal antibody in SKOV3 and OVCAR3 xenografts) 
(45) and cell surface receptors (HER2 expression in SKOV3 
xenografts) (46).
Despite the success in other cancers, the use of 11C-Cho-PET 
has been rarely applied to EOC with limited results (47), and 
to the best of our knowledge, there are no papers on preclinical 
models. Deuterium-substituted 18F-fluoromethyl-[1,2-2H4]-
choline is a recently developed stable radiotracer that overcomes 
the short physical half-life of 11C and seems to be a promising tool 
for choline metabolism imaging for tumors with high PCho level 
such as ovarian cancer (48).
COnCLUSiOn On THe USeFULneSS 
OF MRS AnD Dwi in THe 
MAnAGeMenT OF eOC MODeLS
The use of multidisciplinary approaches including MRI and MRS 
in suitable EOC preclinical models may enhance understanding 
of molecular mechanisms of disease progression and response to 
therapy, eventually leading to the design of improved treatment 
strategies.
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